Skip to content

Study · Ex vivo tissue · 2010

6 results

Kisspeptin-10 inhibits angiogenesis in human placental vessels ex vivo and endothelial cells in vitro.

Ramaesh T, Logie JJ, Roseweir AK, Millar RP, Walker BR, Hadoke PW, Reynolds RM

Endocrinology6 Oct 2010Cited by 43 (Europe PMC)

PMID20926586 (opens in a new tab)DOI10.1210/en.2010-0565 (opens in a new tab)PepBankPUB-20926586
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In explanted human placental arteries, KP-10 inhibited new vessel sprouting in a concentration-dependent manner.

    In plain wordsIn lab tests on human placental arteries, KP-10 reduced new blood vessel sprouting, more so at higher concentrations.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseNew vessel sprouting from placental arteries
    Study

    humann: not reported in source

    explanted human placental arteries in Matrigel
    Outcome group
    Angiogenesis · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-10 inhibited new vessel sprouting from placental arteries embedded in Matrigel and tube-like structure formation by HUVEC, in a concentration-dependent manner.
    1 context sentence
    Summary · context
    The ability of kisspeptin-10 (KP-10) (a shorter biologically active processed peptide) to inhibit angiogenesis was tested in explanted human placental arteries and HUVEC using complementary ex vivo and in vitro assays.
  2. 02LabIn vitro (cells)Efficacy outcome

    In HUVEC, KP-10 inhibited tube-like structure formation in a concentration-dependent manner.

    In plain wordsIn cells, KP-10 reduced the formation of tube-like structures, more so at higher concentrations.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseTube-like structure formation by HUVEC
    Study

    humann: not reported in source

    human umbilical vein endothelial cells (HUVEC)
    Outcome group
    Angiogenesis · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-10 inhibited new vessel sprouting from placental arteries embedded in Matrigel and tube-like structure formation by HUVEC, in a concentration-dependent manner.
    1 context sentence
    Summary · context
    The ability of kisspeptin-10 (KP-10) (a shorter biologically active processed peptide) to inhibit angiogenesis was tested in explanted human placental arteries and HUVEC using complementary ex vivo and in vitro assays.
  3. 03LabIn vitro (cells)Efficacy outcome

    In HUVEC, KP-10 had no effect on cell viability.

    In plain wordsIn cells, KP-10 did not change cell viability.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeHUVEC viability
    Study

    humann: not reported in source

    human umbilical vein endothelial cells (HUVEC)
    Outcome group
    Angiogenesis · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-10 had no effect on HUVEC viability or apoptosis
    1 context sentence
    Summary · context
    The ability of kisspeptin-10 (KP-10) (a shorter biologically active processed peptide) to inhibit angiogenesis was tested in explanted human placental arteries and HUVEC using complementary ex vivo and in vitro assays.
  4. 04LabIn vitro (cells)Efficacy outcome

    In HUVEC, KP-10 had no effect on apoptosis.

    In plain wordsIn cells, KP-10 did not change cell death by apoptosis.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeHUVEC apoptosis
    Study

    humann: not reported in source

    human umbilical vein endothelial cells (HUVEC)
    Outcome group
    Angiogenesis · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-10 had no effect on HUVEC viability or apoptosis
    1 context sentence
    Summary · context
    The ability of kisspeptin-10 (KP-10) (a shorter biologically active processed peptide) to inhibit angiogenesis was tested in explanted human placental arteries and HUVEC using complementary ex vivo and in vitro assays.
  5. 05LabIn vitro (cells)Efficacy outcome

    In HUVEC, KP-10 induced concentration-dependent inhibition of proliferation.

    In plain wordsIn cells, KP-10 slowed cell growth, more so at higher concentrations.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseHUVEC proliferation
    Study

    humann: not reported in source

    human umbilical vein endothelial cells (HUVEC)
    Outcome group
    Angiogenesis · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but induced concentration-dependent inhibition of proliferation and migration.
    1 context sentence
    Summary · context
    The ability of kisspeptin-10 (KP-10) (a shorter biologically active processed peptide) to inhibit angiogenesis was tested in explanted human placental arteries and HUVEC using complementary ex vivo and in vitro assays.
  6. 06LabIn vitro (cells)Efficacy outcome

    In HUVEC, KP-10 induced concentration-dependent inhibition of migration.

    In plain wordsIn cells, KP-10 slowed cell movement, more so at higher concentrations.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseHUVEC migration
    Study

    humann: not reported in source

    human umbilical vein endothelial cells (HUVEC)
    Outcome group
    Angiogenesis · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but induced concentration-dependent inhibition of proliferation and migration.
    1 context sentence
    Summary · context
    The ability of kisspeptin-10 (KP-10) (a shorter biologically active processed peptide) to inhibit angiogenesis was tested in explanted human placental arteries and HUVEC using complementary ex vivo and in vitro assays.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.